Hipertene

Hipertene is an oral medication that contains imidapril hydrochloride as its active ingredient; the specific strength is not disclosed. It belongs to the class of angiotensin‑converting enzyme (ACE) inhibitors and is marketed in the European Union as a prescription product. The formulation is intended for systemic absorption after oral administration. It is supplied in tablet form and is intended for adult patients with elevated blood pressure.

Hipertene is prescribed primarily for the management of high blood pressure.

- Treatment of primary (essential) hypertension in adults. - Adjunct therapy when blood pressure is not controlled with a single agent. - Long‑term management to maintain target blood pressure levels. - Use in patients who require an ACE inhibitor but cannot tolerate other agents.

Like other ACE inhibitors, Hipertene may cause a range of adverse reactions, most of which are mild and transient.

Common: - Dry, persistent cough. - Dizziness or light‑headedness, especially after standing. - Headache. - Fatigue. - Nausea or mild gastrointestinal upset.

Serious: - Angioedema involving the face, lips, tongue, or airway. - Severe hypotension leading to fainting. - Acute kidney injury or worsening renal function. - Hyperkalemia (elevated blood potassium levels).

Before initiating Hipertene, clinicians should evaluate patient history and monitor specific clinical parameters to minimize risk.

- Assess renal function and serum creatinine before and during therapy. - Monitor serum potassium, especially in patients with renal impairment or those taking potassium‑sparing diuretics. - Use caution in patients with a history of angioedema related to ACE inhibitors. - Avoid use during the second and third trimesters of pregnancy. - Review concomitant medications that may increase the risk of hypotension or hyperkalemia. - Consider dose adjustment in elderly patients or those with hepatic impairment.

Hipertene can interact with several drug classes; awareness of these interactions helps prevent adverse outcomes.

Avoid: - Potassium‑supplementing agents (e.g., potassium chloride, potassium‑sparing diuretics) – risk of hyperkalemia. - Aliskiren in patients with diabetes or renal impairment – increased risk of renal dysfunction. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) – may blunt antihypertensive effect and impair renal function.

Use with caution: - Diuretics (especially thiazides) – may cause additive hypotensive effect. - Lithium – ACE inhibitors can increase lithium levels. - Antihyperglycemic agents – may enhance hypoglycemic effect.